Computer-Based Training for Mild Alzheimer's Disease

This study has been completed.
Sponsor:
Collaborator:
University of California, San Francisco
Information provided by:
Posit Science Corporation
ClinicalTrials.gov Identifier:
NCT00319891
First received: April 27, 2006
Last updated: May 13, 2013
Last verified: May 2013
  Purpose

The primary objective of this study is to evaluate the effects of computer-based training program ("HiFi-AD") on the memory and cognitive abilities of individuals diagnosed with mild Alzheimer's Disease (AD).


Condition Intervention Phase
Alzheimer's Disease
Procedure: Computer-based Cognitive Training
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Computer-Based Training for Mild Cognitive Impairment and Mild Alzheimer's Disease

Resource links provided by NLM:


Further study details as provided by Posit Science Corporation:

Primary Outcome Measures:
  • The primary objective of this trial will be to assess the feasibility of using computer-based
  • cognitive training in an a population with early Alzheimer's Disease.

Secondary Outcome Measures:
  • A standardized set of neuropsychological assessments will be conducted pre- and post-
  • compuer-based training.

Estimated Enrollment: 6
Study Start Date: September 2004
Estimated Study Completion Date: October 2006
Primary Completion Date: October 2006 (Final data collection date for primary outcome measure)
Detailed Description:

The purpose of this study is to determine the extent to which computer-based cognitive remediation improves cognitive functions using standardized neuropsychological assessments relevant to AD; 2) the acceptability and feasibility of using computer-based cognitive remediation in an AD population.

  Eligibility

Ages Eligible for Study:   60 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Fluent in English.
  • Mini-Mental Status Examination (MMSE) score of 22 or higher.
  • Adequate visual capacity.
  • Adequate hearing capacity.
  • Has a caregiver with some computer experience.
  • Willing and able to commit to the time requirement of the entire study.

Exclusion Criteria:

  • Clinically significant cerebrovascular disease.
  • Participant is planning to begin acetylcholinesterase inhibitor (AChEI) therapy.
  • Participants with severe tremor.
  • Axis 1 or 2 psychiatric disorders.
  • History of substance abuse.
  • History of head trauma.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00319891

Locations
United States, California
University of California, San Francisco
San Francisco, California, United States, 94143
Sponsors and Collaborators
Posit Science Corporation
University of California, San Francisco
Investigators
Principal Investigator: Joel Kramer, PsyD University of California, San Francisco
Principal Investigator: Kristine Yaffe, MD University of California, San Francisco
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00319891     History of Changes
Other Study ID Numbers: OUT-109-2005
Study First Received: April 27, 2006
Last Updated: May 13, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Posit Science Corporation:
Alzheimer's
AD
Mild Cognitive Impairment
Dementia
Cognitive remediation
computer-based training

Additional relevant MeSH terms:
Alzheimer Disease
Mild Cognitive Impairment
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Cognition Disorders

ClinicalTrials.gov processed this record on September 18, 2014